HLA-C*08:02 is projected to be expressed in ~7% of the total US population, and KRAS G12D–mutant cancers are estimated to arise in at least 4,000 HLA-C*08:02+ patients annually (Gonzalez-Galarza et al. 2021, Pearlman et al. 2021). Here, KRAS is linked to cancer.